Combination of Anti-her2 antibody-drug conjugate and Anti-trop2 antibody-drug conjugate

TW202641586APending Publication Date: 2026-10-16ASTRAZENECA UK LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
TW114149920
Authority / Receiving Office
TW · TW
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-12-20
Filing Date
2025-12-18
Publication Date
2026-10-16

Smart Images

  • Figure TWG2TA001080732_001
    Figure TWG2TA001080732_001
  • Figure TWG2TA001080732_002
    Figure TWG2TA001080732_002
  • Figure TWG2TA001080732_003
    Figure TWG2TA001080732_003
Patent Text Reader

Abstract

A pharmaceutical product for administration of an anti-HER2 antibody-drug conjugate (ADC) in combination with an anti-TROP2 ADC is provided. The anti-HER2 ADC and the anti-TROP2 ADC comprise a drug-linker. An exatecan may be the drug of the drug-linker and the drug-linker may be conjugated to the respective antibody via a thioether bond. Also provided is a therapeutic use and method in which the anti-HER2 ADC and the anti-TROP2 ADC are administered in combination to a subject. The anti-HER2 ADC and anti-TROP2 ADC in combination have excellent anti-cancer properties.
Need to check novelty before this filing date? Find Prior Art